<DOC>
	<DOC>NCT02462707</DOC>
	<brief_summary>The purpose of this study is to determine the recommended Phase 2 dose for PF-03084014 single-agent administration in Japanese patients with advanced solid tumors. Pharmacokinetics and the overall safety profile of PF-03084014 will also be evaluated.</brief_summary>
	<brief_title>A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histological or cytological diagnosis of advanced solid tumors that is resistant to standard therapy or for which no standard therapy is available. Age ≥18 years. ECOG Performance Status (PS) must be 0 or 1. Adequate Bone Marrow Function Adequate Renal Function Adequate Liver Function Resolved acute effects of any prior therapy to baseline severity or Grade ≤1 Patients with known brain metastases Major surgery within 4 weeks of starting study treatment Radiation therapy within 2 weeks of starting study treatment Systemic anti cancer therapy within 2 weeks (4 weeks for antibody) of starting study treatment Previous high dose chemotherapy requiring stem cell rescue Prior irradiation to &gt;25% of the bone marrow Prior treatment with a Notch signal inhibitor Known malabsorption syndrome or other condition that may impair absorption of study medication Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism Current use or anticipated need for known strong and/or moderate CYP3A4 inhibitors Current use or anticipated need for known strong CYP3A4 inducers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>